Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2024:

• 2024 Wells Fargo Healthcare Conference: Fireside chat on September 4 at 3:45 p.m. ET
• Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 6 at 10:00 a.m. ET
• H.C. Wainwright 25th Annual Global Investment Conference: Fireside chat on September 11 at 11:30 a.m. ET

Live webcasts and archived recordings of these events will be available on Avadel's Investor Relations website for 90 days following each conference.

News Market Reaction – AVDL

-5.95%

-5.95% Session move

In the trading session that priced this news, AVDL declined 5.95%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

• 2024 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4 at 3:45 p.m. ET.
• Morgan Stanley 22^nd Annual Global Healthcare Conference: Fireside chat on Friday, September 6 at 10:00 a.m. ET.
• H.C. Wainwright 25^th Annual Global Investment Conference: Fireside chat on Wednesday, September 11 at 11:30 a.m. ET.
  

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162

FAQ

What investor conferences will Avadel Pharmaceuticals (AVDL) attend in September 2024?

Avadel Pharmaceuticals will attend three investor conferences in September 2024: the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.

When is Avadel Pharmaceuticals' (AVDL) fireside chat at the 2024 Wells Fargo Healthcare Conference?

Avadel Pharmaceuticals' fireside chat at the 2024 Wells Fargo Healthcare Conference is scheduled for Wednesday, September 4, 2024, at 3:45 p.m. ET.

Where can investors access the webcasts of Avadel Pharmaceuticals' (AVDL) conference presentations?

Investors can access live webcasts and archived recordings of Avadel Pharmaceuticals' conference presentations on the company's Investor Relations website at investors.avadel.com.

How long will the recordings of Avadel Pharmaceuticals' (AVDL) conference presentations be available?

The recordings of Avadel Pharmaceuticals' conference presentations will be available on their Investor Relations website for 90 days following each conference.